Evaluating Serum Sestrin in Leiomyoma Patients

Sisli Hamidiye Etfal Training and Research Hospital

Status: Completed

Conditions: Uterine Leiomyoma

Treatments: Other: Determination of serum sestrin levels

Study type: Observational

Funder types: Other

Identifiers

NCT04819633

Myomsestrin

Details and patient eligibility

About

Leiomyomas are the most common benign neoplasms of women's reproductive system affecting 20-30% of women within the reproductive ages. Sestrins are serum proteins which are highly expressed under circumstances of DNA damage, hypoxia and oxditive stress and play an important role in autophagia. The aim of this study is to evaluate the relationship of serum sestrin proteins with development of leiomyomas.

Full description

Leiomyomas are the benign neoplasms of uterus and the role of genetics, estrogen levels and obesity has already been shown in their development. Higher levels of serum sestrin proteins have already been associated with DNA damage, hypoxia and oxidative stress and sestrin plays an important role in autophagia. In order to evaluate the role of serum sestrin in the development of leiomyomas 30 patients between 18-45 years of age who were diagnosed with uterine leiomyomas with transvaginal ultrasonography will be included in the study group. Their serum sestrin levels will be determined and compared with that of 30 healthy subjects recruited during the same study period at the same clinic.

Enrollment: 61 patients

Sex: Female

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 18-45 years of age
• patients diagnosed with uterine leiomyomas will be included in the study group
• patients without any additional comorbidities
• patients without any autoimmune diseases

Exclusion criteria

• patients with systemic diseases
• patients with known chronic inflammatory diseases
• patients using hormonal and/or medical therapy
• pregnant women
• lactating women
• patients with malignant diseases

Trial design

61 participants in 2 patient groups

Study Group

Description:

30 patients within the reproductive ages (18-45 years) who were diagnosed with leiomyomas using transvaginal ultrasonography without any additional chronic, systemic or autoimmune disease, are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.

Treatment:

Other: Determination of serum sestrin levels

Control Group

Description:

30 healthy subjects within the reproductive ages (18-45 years) who visited the outpatient gynecological clinic for routine examination who do not have any additional chronic, systemic or autoimmune disease, who are not currently using any medical, hormonal, antiinflammatory treatments are included in this group.

Treatment:

Other: Determination of serum sestrin levels